Insmed (INSM) announced that it intends to offer and sell $650M of shares of its common stock in an underwritten public offering. Goldman Sachs & Co. and Leerink Partners are acting as joint book-running managers for the offering.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INSM:
- Insmed price target raised to $106 from $99 at RBC Capital
- Insmed price target raised to $102 from $90 at Morgan Stanley
- Mizuho ups Insmed target on ‘grand slam’ PAH data
- Buy Rating on Insmed Driven by Promising Phase 2 Results and Strategic Phase 3 Approach for PAH Treatment
- Insmed price target raised to $109 from $94 at BofA
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue